 |
|
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase IV | Treatment | Approved-not yet active | 18 and over | MC#08-002
IIT 12230, NCT00883675 |
Trial Description
Summary The purpose of this study is to determine whether it is safe to treat lung cancer patients who have undergone an attempt at curative resection with the combination of docetaxel and carboplatin. Eligibility Criteria Inclusion Criteria: - Non-small cell lung cancer stage IB - IIIA, complete resection with mediastinal lymph node dissection
- >14 and <56 days since resection
Exclusion Criteria: - Prior chemotherapy and/or radiation therapy for lung cancer
- Peripheral neuropathy > grade 1
- Concurrent other malignancies, other than basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
- Medical condition that will not permit treatment or follow up according to the protocol
- Prior treatment with docetaxel or carboplatin
- Hypersensitivity to polysorbate 80, platinum-containing compounds or mannitol
- Treatment with other investigational anti-cancer drugs within 30 days of registration
- Pregnant or nursing women
Trial Contact Information
Trial Lead Organizations/Sponsors Maestro Clinical, Inc. Sanofi-Aventis - US - Bridgewater
| David M. Jablons | | Principal Investigator |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00883675
Information obtained from ClinicalTrials.gov on April 20, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
